Renal Cell Carcinoma | Clinical

NCCN Guidelines for RCC Add Frontline Lenvatinib/Pembrolizumab as Preferred Treatment Option

April 17, 2021

Recent updates to the National Comprehensive Cancer Network’s guidelines for renal cell carcinoma reflect quick integration of new agents and combination regimens to provide patients with RCC with more treatment options and the most up-to-date options.

Adjuvant Pembrolizumab Prolongs Disease-Free Survival in Renal Cell Carcinoma

April 08, 2021

Treatment with pembrolizumab led to improvement in disease-free survival in patients with renal cell carcinoma following nephrectomy or following nephrectomy and resection of metastatic lesions, meeting the primary end point of the pivotal phase 3 KEYNOTE-564 trial.

Higher Lenvatinib Dose May Improve HRQoL in RCC

April 02, 2021

The standard dose of lenvatinib, 18 mg per day, demonstrated an improved health-related quality of life and a longer time to deterioration over a lower starting dose of lenvatinib, 14 mg per day, in patients with renal cell carcinoma, according to secondary results from a phase 2 trial.